Shire PLC (NASDAQ:SHPG)‘s stock had its “outperform” rating reissued by stock analysts at Royal Bank Of Canada in a note issued to investors on Wednesday. They currently have a $213.00 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 39.87% from the stock’s current price.

A number of other research firms also recently issued reports on SHPG. BidaskClub raised shares of Shire PLC from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. ValuEngine raised shares of Shire PLC from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. HSBC Holdings plc raised shares of Shire PLC from a “reduce” rating to a “hold” rating in a report on Thursday, July 6th. Piper Jaffray Companies set a $159.00 price objective on shares of Shire PLC and gave the stock a “hold” rating in a report on Wednesday, July 26th. Finally, Cantor Fitzgerald set a $222.00 price objective on shares of Shire PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the stock. Shire PLC presently has a consensus rating of “Buy” and an average price target of $220.91.

Shire PLC (NASDAQ SHPG) traded up 0.85% during midday trading on Wednesday, reaching $153.58. The company’s stock had a trading volume of 346,302 shares. The company has a market cap of $45.74 billion, a PE ratio of 68.72 and a beta of 1.63. The stock has a 50-day moving average price of $153.21 and a 200 day moving average price of $165.31. Shire PLC has a 12 month low of $139.36 and a 12 month high of $194.60.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Analysts expect that Shire PLC will post $14.93 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.watchlistnews.com/shire-plc-shpg-stock-rating-reaffirmed-by-royal-bank-of-canada/1628296.html.

Several hedge funds have recently added to or reduced their stakes in SHPG. American International Group Inc. increased its position in shares of Shire PLC by 1.2% in the first quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock valued at $803,000 after acquiring an additional 54 shares during the period. Neuberger Berman Group LLC increased its position in shares of Shire PLC by 7.9% in the first quarter. Neuberger Berman Group LLC now owns 14,944 shares of the biopharmaceutical company’s stock valued at $2,604,000 after acquiring an additional 1,095 shares during the period. United Services Automobile Association increased its position in shares of Shire PLC by 4.1% in the first quarter. United Services Automobile Association now owns 16,225 shares of the biopharmaceutical company’s stock valued at $2,827,000 after acquiring an additional 641 shares during the period. Stephens Inc. AR purchased a new position in shares of Shire PLC in the first quarter valued at about $179,000. Finally, MARSHALL WACE ASIA Ltd purchased a new position in shares of Shire PLC in the first quarter valued at about $3,515,000. Hedge funds and other institutional investors own 19.28% of the company’s stock.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.